From *...

From * article:
https://unauthorised investment advice/experts/scopos-powerplays-antisense-looks-like-it-wants-to-run-harder/

Powerplay: Antisense

Power’s pick this week is Antisense Therapeutics (ASX:ANP), a biopharmaceutical company that is researching a potential treatment for Duchenne’s muscular dystrophy.“ The company has made strong progress recently but we view the next 12 months as particularly important with a large number of catalysts and events unfolding giving further clarity on costs, trial design, new indication and potential for partnering discussions to commence,” Morgans said in a research report in February. The company is working on possible new indications for its drug candidate and could soon announce details about a pivotal European phase 3 drug trial. ANP shares are already up 76 per cent this year to 23c.“ That’s one that’s had a good run — but it really looks like it wants to run harder.” Morgans rates Antisense a speculative buy with a price target of 37.7c.